NCT07503002

Shortened LSD Intervention for Major Depressive Disorder

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 21 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.

Detailed description

This study will administer open-label oral LSD hemi-L-tartrate 250 µg followed 45 minutes later by oral risperidone 1 mg to 10 participants with Major Depressive Disorder (MDD) for a pilot investigation into the effects of abbreviated LSD on depression. Participants will be monitored for 10.5 hours and assessed for subjective effects and discharge readiness at several time points following the dose. The main aim of this study is to test whether risperidone can be used to abbreviate the subjective effects of LSD, and whether this abbreviated LSD experience will have any potential therapeutic benefit in patients with MDD.

Conditions

• Major Depression Moderate
• Major Depression Severe
• Major Depression

Interventions

Type	Name	Description
DRUG	LSD	Participants will be administered LSD followed 45-minutes later by risperidone.
DRUG	Risperidone	Participants will be administered LSD followed 45-minutes later by risperidone.

Timeline

• Start date: 2026-07-01
• Primary completion: 2027-07-01
• Completion: 2027-12-01
• First posted: 2026-03-31
• Last updated: 2026-04-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study